Epidarex Portfolio News

EPIDAREX CAPITAL – CATALYZING INNOVATION IN HEALTH SCIENCE AND TECHNOLOGY


Category: Epidarex Portfolio News

New Pivotal Data Demonstrate Superiority of Apellis’ Pegcetacoplan to Eculizumab in Improving Hemoglobin Levels, Independent of Prior Transfusions, in PNH

71% of pegcetacoplan-treated patients achieved LDH normalization vs. 15% of eculizumab-treated patients 73% of pegcetacoplan-treated patients achieved a clinically meaningful improvement in FACIT-fatigue score vs. 0% of eculizumab-treated patients   Detailed results from positive head-to-head Phase 3 PEGASUS study in patients with paroxysmal nocturnal hemoglobinuria…

NodThera Announces Close of $55 Million Series B Financing

Financing round led by Novo Ventures and includes new investors Cowen Healthcare Investments and Sanofi Ventures, as well as existing investors 5AM Ventures, F-Prime Capital, Sofinnova Partners and founding investor Epidarex Capital  Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including…